Median Technologies' Eyonis LCS, an AI tool for low-dose CT lung cancer screening, receives FDA clearance.
Key Details
- 1Median Technologies received FDA clearance for Eyonis LCS, an AI/ML-powered computer-aided detection software as a medical device.
- 2Designed to assist in the interpretation of low-dose CT (LDCT) scans for lung cancer screening, addressing inter-reader variability.
- 3Eyonis LCS is reported as the first end-to-end FDA-cleared device specifically for lung cancer screening workflows.
- 4Performance testing showed 93.3% sensitivity, 92.4% specificity, and 99.9% negative predictive value (NPV).
- 5The tool is aimed at improving screening access and diagnostic accuracy, as well as reducing unnecessary procedures.
Why It Matters
FDA clearance for Eyonis LCS marks a significant advancement in AI-assisted lung cancer screening by leveraging CT imaging. The device's strong performance metrics and focus on workflow efficiency could help radiology practices meet increasing screening demands while improving patient outcomes.
Source
Radiology Business
Related News
•Radiology Business
Framework Assesses Real-World Financial Impact of Radiology AI Adoption
A new analysis presents a financial calculator for objectively assessing the return on investment (ROI) of implementing radiology AI solutions.
•Radiology Business
Study Finds Disparities in Access to Stroke Imaging AI Tools
Research shows access to AI stroke detection tools is concentrated in resource-rich hospitals despite Medicare incentives.
•Cardiovascular Business
AI Is Quietly Embedded in Cardiac Imaging Workflows
AI is now seamlessly integrated into cardiac imaging, often unnoticed by clinicians.